Approval

CureVac Withdraws Application For Approval Of Its MRNA Vaccine

October 14,2021 09:56 AM
- By Admin

CureVac’s shot was highly anticipated as unlike other mRNA vaccines, it can be stored in regular refrigerators and remains stable for 24 hours at room temperature.​ German biotech firm CureVac has withdrawn the application for approval of its mRNA vaccine in Europe after disappointing trial results. The company said late-stage trials showed the vaccine had an efficacy of 47%, below the WHO-set threshold for Covid-19 vaccine.


CureVac’s shot, one of the many “slow vaccines” that could have plugged the vaccine gap in the developing countries, was highly anticipated as unlike other mRNA vaccines — of Pfizer and Moderna — it can be stored in regular refrigerators and remains stable for 24 hours at room temperature.

Abandoning the vaccine will allow the company to focus on its second-generation vaccine designed specifically for new variants of the virus and on combination shots that could prevent two or more infectious diseases. Clinical trials for its second-generation shot could start in the coming months, with potential regulatory approval in 2022. Trials in animals showed them to be superior to CureVac's original Covid-19 vaccine.